Form 4: AN2 Therapeutics CEO Granted Significant Equity Awards

AN2 Therapeutics CEO Eric Easom was granted 112,250 restricted stock units and 224,500 stock options, effective February 20, 2026.

Summary

• Eric Easom, CEO and Director of AN2 Therapeutics, Inc. (ANTX), reported an acquisition of equity securities.
• The transaction date for these acquisitions is February 20, 2026.
• Easom acquired 112,250 shares of Common Stock in the form of Restricted Stock Units (RSUs) at a price of $0.
• These RSUs will vest annually over four years, with 1/4th vesting from January 1, 2026, contingent on continuous service.
• Easom also acquired 224,500 Stock Options (right to buy) with an exercise price of $1.04 per share.
• These stock options will vest monthly over four years, with 1/48th vesting from January 1, 2026, contingent on continuous service, and expire on February 19, 2036.
• Following these transactions, Easom directly beneficially owns 368,630 shares of Common Stock (including previously granted RSUs with vesting schedules from January 1, 2025, and January 1, 2024) and 224,500 derivative stock options.
• Indirect beneficial ownership includes 1,065,766 shares held by the Easom Living Trust, 97,058 shares by the C. Easom Irrevocable Trust, and 97,058 shares by the Jude Easom Irrevocable Trust.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies continued executive commitment and aligns management incentives with shareholder interests through long-term equity awards, a standard and generally favorable practice.

Positives

• The grant of restricted stock units and stock options aligns the CEO's interests with long-term shareholder value through equity ownership.
• Equity compensation is a standard practice to incentivize executive performance and retention.

Negatives

• The issuance of new equity awards could lead to minor dilution for existing shareholders over time as RSUs vest and options are exercised.

Risks

• The value of the equity awards is subject to the future performance of AN2 Therapeutics' stock price.
• Vesting of both RSUs and stock options is contingent upon Eric Easom's continuous service to the company, posing a risk to the full realization of the awards if service is terminated.

Future Outlook

The filing indicates future vesting schedules for restricted stock units and stock options, extending through January 1, 2026, and beyond, contingent on the CEO's continuous service. This suggests a long-term commitment to executive retention and performance incentives.

Industry Context

StockSavvy.ai notes that equity grants, such as restricted stock units and stock options, are a prevalent form of executive compensation in the biotechnology and pharmaceutical sectors. This practice is designed to align the interests of management with those of shareholders, encouraging long-term value creation and retention in a highly competitive industry where talent is critical for drug development and commercialization success.

Comparison to Industry Standards

• The structure of four-year vesting for both RSUs and stock options is a common industry standard for executive equity compensation, comparable to practices seen at companies like Moderna (MRNA) or BioNTech (BNTX) for their key executives, aiming for long-term retention and performance alignment.
• The grant size for a CEO of a company like AN2 Therapeutics, which is in the clinical-stage biotechnology space, appears to be within typical ranges for incentivizing leadership in a high-risk, high-reward industry, though specific comparisons would require detailed peer group analysis.

Related Party Transactions

• Indirect beneficial ownership of Common Stock is held through the Easom Living Trust, the C. Easom Irrevocable Trust, and the Jude Easom Irrevocable Trust, which are related entities to Eric Easom.

Stakeholder Impact

• Shareholders: Potential for minor dilution from the vesting and exercise of new equity awards, but also improved alignment of CEO incentives with long-term company performance.
• Employees: The CEO's continued equity grants may signal stability and confidence in the company's future, potentially impacting employee morale.

Next Steps

• The 112,250 RSUs will begin vesting annually over four years from January 1, 2026.
• The 224,500 stock options will begin vesting monthly over four years from January 1, 2026.

Key Dates

Keywords

AN2 Therapeutics, ANTX, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Stock Options, CEO Compensation, Executive Compensation, Beneficial Ownership